Phase 1 Refractory Osteosarcoma Clinical Trials
6 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–6 of 6 trials
Recruiting
Phase 1Phase 2
Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)
Relapsed / Refractory Osteosarcoma
Lantheus Medical Imaging55 enrolled2 locationsNCT07357519
Recruiting
Phase 1Phase 2
Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Recurrent Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmRecurrent Solid Tumor+19 more
St. Jude Children's Research Hospital90 enrolled10 locationsNCT04901702
Recruiting
Phase 1
Tegavivint With Gemcitabine in Patients With Relapsed or Refractory Osteosarcoma
Refractory OsteosarcomaOsteosarcoma in ChildrenOsteosarcoma Recurrent+1 more
Emory University24 enrolled1 locationNCT07144254
Recruiting
Phase 1Phase 2
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Ovarian CarcinomaColorectal CarcinomaMelanoma+19 more
Children's Oncology Group147 enrolled21 locationsNCT04851119
Recruiting
Phase 1
Genetically Engineered Cells (FH-FOLR1 ST CAR T Cells) for the Treatment of Advanced Refractory or Recurrent/Progressive Osteosarcoma, FIERCe Trial
Recurrent OsteosarcomaRefractory OsteosarcomaAdvanced Osteosarcoma
Fred Hutchinson Cancer Center30 enrolled1 locationNCT07227571
Recruiting
Phase 1
Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed /Refractory Neuroblastoma or Refractory/ Relapsed Osteosarcoma
NeuroblastomaRefractory OsteosarcomaRefractory Neuroblastoma+2 more
Emory University24 enrolled1 locationNCT05400603